STEPHENSON BRIAN C 4
4 · BridgeBio Pharma, Inc. · Filed Feb 27, 2025
Insider Transaction Report
Form 4
STEPHENSON BRIAN C
Secretary, Treasurer & CFO
Transactions
- Exercise/Conversion
Common Stock
2025-02-25$17.00/sh+8,500$144,500→ 110,964 total - Sale
Common Stock
2025-02-25$33.18/sh−8,400$278,697→ 102,564 total - Exercise/Conversion
Stock Option (right to buy)
2025-02-25−8,500→ 440,170 totalExercise: $17.00Exp: 2029-06-26→ Common Stock (8,500 underlying) - Sale
Common Stock
2025-02-25$34.18/sh−100$3,418→ 102,464 total
Footnotes (3)
- [F1]This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 22, 2024.
- [F2]Represents the weighted average sale price of the shares sold from $32.63 to $33.53 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.
- [F3]The shares subject to this option vested in 48 equal monthly installments from June 26, 2019 to June 26, 2023.